Formosa Laboratories Inc (4746) - Total Liabilities
Based on the latest financial reports, Formosa Laboratories Inc (4746) has total liabilities worth NT$5.01 Billion TWD (≈ $157.97 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Formosa Laboratories Inc (4746) long-term investment share to see how much of total assets are deployed in long-term investments.
Formosa Laboratories Inc - Total Liabilities Trend (2009–2025)
This chart illustrates how Formosa Laboratories Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Formosa Laboratories Inc (4746) total assets.
Formosa Laboratories Inc Competitors by Total Liabilities
The table below lists competitors of Formosa Laboratories Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Forte Biosciences Inc
NASDAQ:FBRX
|
USA | $12.99 Million |
|
Neto M.E Holdings Ltd
TA:NTO
|
Israel | ILA1.21 Billion |
|
Sriracha Construction Public Company Limited
BK:SRICHA
|
Thailand | ฿1.58 Billion |
|
Amaero Ltd
AU:3DA
|
Australia | AU$36.85 Million |
|
SFP Tech Holdings Bhd
KLSE:0251
|
Malaysia | RM104.74 Million |
|
Home Center Holdings Co.Ltd
KQ:060560
|
Korea | ₩293.88 Billion |
|
Readly International AB
ST:READ
|
Sweden | Skr223.73 Million |
|
Draganfly Inc
NASDAQ:DPRO
|
USA | $5.35 Million |
Liability Composition Analysis (2009–2025)
This chart breaks down Formosa Laboratories Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 4746 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.33 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.64 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.37 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Formosa Laboratories Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Formosa Laboratories Inc (2009–2025)
The table below shows the annual total liabilities of Formosa Laboratories Inc from 2009 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$5.16 Billion ≈ $162.67 Million |
-1.63% |
| 2024-12-31 | NT$5.25 Billion ≈ $165.36 Million |
-3.27% |
| 2023-12-31 | NT$5.43 Billion ≈ $170.95 Million |
+9.52% |
| 2022-12-31 | NT$4.95 Billion ≈ $156.09 Million |
+12.22% |
| 2021-12-31 | NT$4.41 Billion ≈ $139.09 Million |
-11.70% |
| 2020-12-31 | NT$5.00 Billion ≈ $157.53 Million |
-2.93% |
| 2019-12-31 | NT$5.15 Billion ≈ $162.29 Million |
+23.60% |
| 2018-12-31 | NT$4.17 Billion ≈ $131.30 Million |
+32.68% |
| 2017-12-31 | NT$3.14 Billion ≈ $98.96 Million |
+19.39% |
| 2016-12-31 | NT$2.63 Billion ≈ $82.89 Million |
-12.13% |
| 2015-12-31 | NT$2.99 Billion ≈ $94.33 Million |
+12.76% |
| 2014-12-31 | NT$2.66 Billion ≈ $83.65 Million |
+7.27% |
| 2013-12-31 | NT$2.48 Billion ≈ $77.99 Million |
+4.83% |
| 2012-12-31 | NT$2.36 Billion ≈ $74.39 Million |
+91.41% |
| 2011-12-31 | NT$1.23 Billion ≈ $38.87 Million |
+25.63% |
| 2010-12-31 | NT$981.92 Million ≈ $30.94 Million |
+172.92% |
| 2009-12-31 | NT$359.78 Million ≈ $11.33 Million |
-- |
About Formosa Laboratories Inc
Formosa Laboratories, Inc., together with its subsidiaries, engages in the manufacture and sale of active pharmaceutical ingredients (APIs) and ultraviolet absorbers in India, the Netherlands, Japan, Germany, Taiwan, China, Switzerland, the United States, Canada, and internationally. It offers APIs in the areas of anticancer, vitamin D derivatives, anti-inflammatory and analgesic agents, immunomo… Read more